What can our technology achieve?
Our multi-patented Controlled Expansion of Supercritical Solutions (CESS®) technology enables the creation of API nanoparticles directly from solution. The process can be applied to most small molecules, with a high success rate of 80-90%.
Benefits of CESS®
Controlled
particle shape
Our nanoformingTM process can control the shape of particles, leading to greater uniformity.
Controlled
particle size
Our technology can produce nanoparticles as small as 10 nm. Smaller particles have greater active surface areas, which permits an increased rate of dissolution.
Controlled
polymorphism
Polymorphic purity tests have shown that stable single polymorphs can be produced with defined process parameters enabling polymorphic control.
How does CESS® work?
CESS® is a bottom-up method of recrystallization that works by controlling the solubility of an API in supercritical carbon dioxide (scCO2). The use of scCO2 permits a green particle engineering process with pharmaceutical CO2 that is free from excipients and organic solvents. CESS® represents a significant improvement over previous supercritical technologies due to the employment of controlled mass transfer, flow and pressure reduction.
Before NanoformingTM
| mag | det | HV | spot | pressure | dwell | 40µm |
| 2 500 | xLFD | 3.00 kV | 3.0 | 39 Pa | 20µm | label |
After NanoformingTM
| mag | det | HV | spot | pressure | dwell | 5µm |
| 16 500 | xLFD | 10.00 kV | 3.0 | 41 Pa | 20µm | label |
Nanoform’s unique STARMAP®
nanoformingTM technology database.
We are implementing the use of sparse data AI for enhanced drug development through our STARMAPTM nanoformingTM technology. This utilization of AI, in combination with our particle engineering technology, will help deepen our understanding of how drug candidate physical and chemical characteristics affect solubility and bioavailability. This will enable us to predict the nanoformingTM success for new drug candidates
